Michael Severino - AbbVie President
4AB Stock | EUR 159.44 2.56 1.63% |
President
Dr. Michael E. Severino, M.D., is President, Vice Chairman of the Company. Dr. Severino is AbbVie Executive Vice President, Research and Development and Chief Scientific Officer since 2018.
Age | 51 |
Tenure | 6 years |
Phone | 847 932 7900 |
Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Derica Rice | Eli Lilly and | 51 | |
Jeffrey Simmons | Eli Lilly and | 48 | |
Stephen Fry | Eli Lilly and | 50 | |
Jan Lundberg | Eli Lilly and | 62 | |
Leigh Pusey | Eli Lilly and | 60 | |
Alfonso Zulueta | Eli Lilly and | 53 | |
David Ricks | Eli Lilly and | 55 | |
Maria Crowe | Eli Lilly and | 55 | |
Enrique Conterno | Eli Lilly and | 49 | |
Joshua Smiley | Eli Lilly and | 47 | |
Melissa Barnes | Eli Lilly and | 47 | |
Barton Peterson | Eli Lilly and | 57 | |
Susan Mahony | Eli Lilly and | 51 | |
Darren Carroll | Eli Lilly and | N/A | |
Michael Harrington | Eli Lilly and | 53 | |
Fionnuala Walsh | Eli Lilly and | 56 |
Management Performance
Return On Equity | 0.72 | |||
Return On Asset | 0.0991 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carlos Alban, Executive Vice President - Commercial Operations | ||
Robert Michael, Vice President Controller | ||
Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
Brett Hart, Independent Director | ||
William Chase, Executive Vice President CFO | ||
Roxanne Austin, Independent Director | ||
Perry Siatis, Gen VP | ||
Azita SalekiGerhardt, Senior Vice President - Operations | ||
Scott Reents, VP CFO | ||
Edward Rapp, Independent Director | ||
Richard Gonzalez, Chairman of the Board, CEO | ||
Brian Durkin, Vice President Controller | ||
Thomas Hurwich, Vice President Controller | ||
Frederick Waddell, Independent Director | ||
Robert Alpern, Independent Director | ||
Thomas Hudson, VP Officer | ||
Glenn Tilton, Lead Independent Director | ||
Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
Elizabeth Shea, VP Relations | ||
Rebecca Roberts, Independent Director | ||
Edward Liddy, Independent Director | ||
William Burnside, Independent Director | ||
Timothy Richmond, Senior Vice President - Human Resources | ||
Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
Roy Roberts, Independent Director | ||
Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.72 | |||
Return On Asset | 0.0991 | |||
Profit Margin | 0.20 % | |||
Operating Margin | 0.39 % | |||
Current Valuation | 331.38 B | |||
Shares Outstanding | 1.77 B | |||
Shares Owned By Insiders | 0.12 % | |||
Shares Owned By Institutions | 71.51 % | |||
Price To Earning | 22.27 X | |||
Price To Book | 18.07 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AbbVie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AbbVie's short interest history, or implied volatility extrapolated from AbbVie options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Stocks Directory Find actively traded stocks across global markets | |
CEOs Directory Screen CEOs from public companies around the world |